What's Hot
View all perspectives
Dr. John Cush RheumNow
2 years 5 months ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.
David Liew drdavidliew
2 years 5 months ago
Just so good to see PMR on the plenary stage at #ACR22, after #EULAR2022 too
SAPHYR study: sarilumab allows for
- a quicker steroid wean & less toxicity
- but also far more disease remission, quicker symptom resolution, better quality of life
Game-changing.
ABST1676 @RheumNow https://t.co/ZVqlMNoniu https://t.co/Fv3VRZrKGe
Janet Pope Janetbirdope
2 years 5 months ago
Do you think you need a #steroid sparing Rx in #polymyalgia #rheumatica? +data in #sarilumab w 14 wk ped taper. No diverticulitis, ?Stacking comparator grp to flare as past steroid tapering caused a flare. But that is an unmet need after long pred Rx Abst#1543 #ACR22 @RheumNow https://t.co/Q1bhYs7LEz
Mike Putman EBRheum
2 years 5 months ago
Intersting discussion post Plenary this AM
- Agree w/RS that we should taper steroid
- Is there a disease modifying benefit? I think not
- When should this be used? Disagree w/RS, I would not use unless relapsing/refractory and requiring >10mg pred
#ACR22 @RheumNow https://t.co/ylGXk2sca7
Robert B Chao, MD doctorRBC
2 years 5 months ago
Study shows no progressive increase of MRI structural lesions in SI joints of health individuals with increasing age, including:
Bone marrow edema, erosions, fat lesions
Abs#2258 @RheumNow #ACR22 https://t.co/W2dkRCAPc4
Catherine Sims, MD DrCassySims
2 years 5 months ago
SSc and DM/PM can cause disease related sexual dysfunction ➡️ consider pelvic floor PT
Abstract #0940 #ACR22 @RheumNow
🧘♀️8 week PT program targeting pelvic floor exercises and MSK issues impacting sexual function
🧘Women experienced sig. improved sexual function and QOL
Eric Dein ericdeinmd
2 years 5 months ago
Ab1677 #ACR22 by @MaxKonigMD
Chimeric autoAg T cell recepter (CATCR) reprogram T cells to selectively kill autoreactive B cells
Model CATCR for APLS via B2GPI-CATCR T-cells eliminating anti-B2GP DI B cells, dose-dependent
Model for SELECTIVE Rx in APLS/rheum disease
@RheumNow https://t.co/jMpMu10phL
Mike Putman EBRheum
2 years 5 months ago
Very cool preclinical plenary @MaxKonigMD
Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells)
Early days but super interesting possibilities - APS, SLE, AAV, & more?
#ACR22 @rheumnow #ACRBest Abstr#1677 https://t.co/nS3YtR6wN9
Janet Pope Janetbirdope
2 years 5 months ago
#ACR22 highlights. #PMR May have Steroid sparing options. #tocilizumab abst#1106, #tofacitinib abst1107, #sarilumab #1676. Also previous #secukinumab ALL positive RCTs #ACRBest @RheumNow
Richard Conway RichardPAConway
2 years 5 months ago
Izmirly et al. HCQ crosses placenta but no evidence ocular toxicity in children at 5 years old by OCT @RheumNow #ACR22 Abstr#1674 https://t.co/yMQzt6sU7i
David Liew drdavidliew
2 years 5 months ago
Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies:
precision cellular therapy
selectively deplete autoreactive B cells
@MaxKonigMD in the plenary:
CATCR can take out anti-b2GPI autoAbs crucial to antiphospholipid syndrome, but preserve normal B cells
#ACR22 @RheumNow https://t.co/5ZLocrwqKY
Julian Segan JulianSegan
2 years 5 months ago
GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently.
@RheumNow #ACR22 #Plenary
Janet Pope Janetbirdope
2 years 5 months ago
#ACR22 Highlights. ILD in CTDs #rituximab = #cyclophoshamide at 6 mo for CTD ILD & ritux better on skin score in #scleroderma RECITAL RCT abst0003 but #pirfenidone added to #MMF not better than MMF alone in SLSIII RCT—ILD w #SSc abst#520 vs in SENCIS #nintedanib is + @RheumNow
Mike Putman EBRheum
2 years 5 months ago
Great moderating PMR talk w/@SattuiSEMD this AM; phenomenal slides @drceowen re:imaging in PMR
Big ?s:
-Who needs this? All/some/many
-Which modality? Nice summary slide
-How to treat "subclinical" GCA (risk of overtreatment imo)
Ideas for next year?
#ACR22 @rheumnow #ACRBest https://t.co/akvsud3YVO
Poster Hall